Shin Nippon Biomedical Laboratories Valuation

Is YB3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of YB3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: YB3 (€7.15) is trading below our estimate of fair value (€11.66)

Significantly Below Fair Value: YB3 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for YB3?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for YB3. This is calculated by dividing YB3's market cap by their current preferred multiple.
What is YB3's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	JP¥47.29b

YB3 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.7x
Enterprise Value/EBITDA	14.8x
PEG Ratio	1.2x

Price to Earnings Ratio vs Peers

How does YB3's PE Ratio compare to its peers?

The above table shows the PE ratio for YB3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	22.5x
GXI Gerresheimer	30x	22.1%	€3.5b
1SXP SCHOTT Pharma KGaA	32.4x	15.9%	€4.9b
PSG PharmaSGP Holding	13.9x	12.9%	€251.8m
FYB Formycon	13.6x	30.5%	€870.5m
YB3 Shin Nippon Biomedical Laboratories	11x	9.1%	€47.3b

Price-To-Earnings vs Peers: YB3 is good value based on its Price-To-Earnings Ratio (11x) compared to the peer average (22.5x).

Price to Earnings Ratio vs Industry

How does YB3's PE Ratio compare vs other companies in the European Life Sciences Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	25.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	25.8%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: YB3 is good value based on its Price-To-Earnings Ratio (11x) compared to the European Life Sciences industry average (49.9x).

Price to Earnings Ratio vs Fair Ratio

What is YB3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

YB3 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	11x
Fair PE Ratio	12.5x

Price-To-Earnings vs Fair Ratio: YB3 is good value based on its Price-To-Earnings Ratio (11x) compared to the estimated Fair Price-To-Earnings Ratio (12.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst YB3 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	€7.15	€8.53 +19.3%	11.9%	€9.55	€7.51	n/a	2
Sep ’25	€7.45	€8.29 +11.2%	11.9%	€9.27	€7.30	n/a	2
Aug ’25	€7.40	€8.94 +20.8%	3.4%	€9.25	€8.63	n/a	2
May ’25	€8.95	€19.25 +115.1%	11.1%	€21.39	€17.11	n/a	2
Apr ’25	€9.10	€19.25 +111.5%	11.1%	€21.39	€17.11	n/a	2
Mar ’25	€9.65	€22.80 +136.2%	23.3%	€28.11	€17.49	n/a	2
Feb ’25	€10.50	€22.68 +116.0%	23.3%	€27.97	€17.40	n/a	2
Jan ’25	€10.50	€22.68 +116.0%	23.3%	€27.97	€17.40	n/a	2
Dec ’24	€9.85	€22.68 +130.3%	23.3%	€27.97	€17.40	n/a	2
Nov ’24	€10.30	€23.40 +127.2%	23.3%	€28.85	€17.95	n/a	2
Oct ’24	€11.60	€23.40 +101.7%	23.3%	€28.85	€17.95	n/a	2
Sep ’24	€13.70	€23.40 +70.8%	23.3%	€28.85	€17.95	€7.45	2
Aug ’24	€13.10	€23.32 +78.0%	23.3%	€28.76	€17.89	€7.40	2
Jul ’24	€13.20	€23.32 +76.7%	23.3%	€28.76	€17.89	€7.90	2
Jun ’24	€15.60	€24.54 +57.3%	18.9%	€29.84	€18.57	€7.80	3
May ’24	€16.20	€24.50 +51.2%	26.2%	€30.63	€15.65	€8.95	3
Apr ’24	€18.40	€30.57 +66.2%	13.6%	€34.74	€26.40	€9.10	2
Mar ’24	€18.60	€30.57 +64.4%	13.6%	€34.74	€26.40	€9.65	2
Feb ’24	€15.00	€29.68 +97.8%	9.5%	€32.50	€26.85	€10.50	2
Jan ’24	€15.60	€28.95 +85.6%	9.5%	€31.71	€26.19	€10.50	2
Dec ’23	€18.50	€28.92 +56.3%	9.5%	€31.67	€26.17	€9.85	2
Nov ’23	€17.40	€28.25 +62.4%	8.4%	€30.63	€25.87	€10.30	2
Oct ’23	€18.50	€25.70 +38.9%	5.6%	€27.13	€24.27	€11.60	2

Analyst Forecast: Target price is less than 20% higher than the current share price.